Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company daily Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E21.09 EPS (ttm)2.66 Insider Own0.20% Shs Outstand1.67B Perf Week-0.66%
Market Cap93.81B Forward P/E18.17 EPS next Y3.08 Insider Trans-3.14% Shs Float1.67B Perf Month-0.71%
Income4.46B PEG1.46 EPS next Q0.75 Inst Own71.60% Short Float2.10% Perf Quarter-4.00%
Sales19.43B P/S4.83 EPS this Y184.60% Inst Trans0.52% Short Ratio2.69 Perf Half Y0.57%
Book/sh9.66 P/B5.80 EPS next Y10.02% ROA13.50% Target Price55.46 Perf Year-8.49%
Cash/sh3.79 P/C14.77 EPS next 5Y14.47% ROE29.20% 52W Range46.01 - 76.09 Perf YTD-3.47%
Dividend1.56 P/FCF- EPS past 5Y4.20% ROI20.00% 52W High-26.35% Beta1.08
Dividend %2.78% Quick Ratio1.40 Sales past 5Y-1.80% Gross Margin74.60% 52W Low21.80% ATR1.04
Employees25000 Current Ratio1.60 Sales Q/Q22.30% Oper. Margin30.80% RSI (14)55.68 Volatility1.72% 1.61%
OptionableYes Debt/Eq0.41 EPS Q/Q550.30% Profit Margin22.90% Rel Volume0.85 Prev Close55.89
ShortableYes LT Debt/Eq0.35 EarningsApr 27 BMO Payout57.00% Avg Volume13.03M Price56.04
Recom2.40 SMA20-1.36% SMA503.49% SMA200-4.46% Volume11,108,673 Change0.27%
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Mar-27-17 07:00PM  Warren, Democrats Write Icahn About Advising Trump
04:29PM  3 Top Cancer Drug Stocks to Buy in 2017 at Motley Fool
04:13PM  Can Pfizer Boost Its Value By $5 Billion By Taking Over Bristol?
03:20PM  Senators press Icahn on White House influence, business conflicts Reuters
12:55PM  Pfizer Stock Rises on Bristol-Myers Takeover Talk at Investopedia
10:22AM  Bristol-Myers: Maybe a Pfizer Acquisition Could Makes Sense After All? at
Mar-24-17 12:59PM  Bristol-Myers Opdivo Gets CHMP Nod for Head, Neck Cancer at Investopedia
08:31AM  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy Business Wire
07:47AM  Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
06:46AM  Merck KGaA Shares Spike After FDA Approves Skin Cancer Treatment
Mar-23-17 04:32PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers
Mar-22-17 04:34PM  Dow's Merck Swipes Immuno-Oncology Share From Heavyweight Rivals
02:55PM  Biotech giant plans $25M Tampa investment, 450 jobs at
10:37AM  Durvalumab and Tagrisso May Boost AstraZenecas Revenues in 2017
Mar-21-17 11:26AM  Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
11:00AM  ONCYF: Oncolytic Viruses Emerging as Effective Cancer Treatment
09:18AM  6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
Mar-20-17 04:10PM  Bristol-Myers Partner Hits 18-Month High On Immuno-Oncology Deal
02:26PM  Heres Why Wells Fargo, eBay, CytomX Therapeutics, Dominion Diamond, and More Are Trending at Insider Monkey
12:52PM  Bristol-Myers, CytomX Extend Cancer Drug Pact at Investopedia
11:10AM  A small drug company that's trying to make cancer treatments safer just received a $3.8 billion endorsement
10:55AM  Mondays Top Biopharma Movers
09:38AM  Stocks Edge Lower At The Open; Sprouts Up Again On Merger Talk
09:21AM  CytomX Soars on Bristol-Myers Partnership
09:08AM  3 Top Stocks on Sale This Spring at Motley Fool
09:06AM  Changes in Bristol-Myers Squibbs Profitability in 2016
07:36AM  How BMYs Neuroscience, Immunoscience Segments Performed in 2016
07:18AM  CytomX's stock rockets after expanding Bristol-Myers collaboration at MarketWatch
06:59AM  Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody Therapeutics for the Treatment of Cancer and Other Diseases Business Wire
03:00AM  European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade
Mar-17-17 04:22PM  Dow, S&P 500 Decline as Health Care Losses Counter Gains
04:03PM  Fired U.S. Attorney Preet Bharara Was Investigating HHS Chief Tom Price - Report
02:41PM  Broad Gains Overshadow Health Care Losses to Boost Wall Street
12:03PM  3 Best Pharmaceutical Stocks for Long-Term Investors at Motley Fool
11:15AM  Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation Business Wire
10:37AM  What Cardiovascular Drug Eliquiss 2016 Looked Like
09:06AM  How BMYs Virology Segment Performed in 2016
07:38AM  A Look at Opdivos Performance in 2016
Mar-16-17 04:35PM  How Bristol-Myers Squibbs Oncology Segment Performed in 2016
03:05PM  Analyzing Bristol-Myers Squibbs 2016 Performance
01:21PM  Bristol-Myers Squibbs Valuation Compared to Its Peers
Mar-15-17 04:25PM  Merck Could Be Nearing This Rival With Another Keytruda Approval
10:55AM  Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
09:32AM  Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
07:36AM  Johnson & Johnsons Major Developments
Mar-14-17 06:23PM  Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing at Motley Fool
07:39AM  Why Did the Healthcare Sector Fall on March 13?
07:23AM  The 3 Most Important Numbers for Exelixis, Inc. at Motley Fool
Mar-13-17 01:09PM  US STOCKS-Wall St dips as drug stocks drag; Fed meeting in focus
01:05PM  There's tremendous churn beneath the surface of the seemingly calm stock market
Mar-12-17 11:41AM  3 Big Pharma Stocks To Buy in Your 401(k) at Motley Fool
Mar-10-17 04:41PM  Top Stocks Billionaires Are Buying Now at Motley Fool
10:20AM  Bristol-Myers Squibb to Announce Results for First Quarter 2017 on April 27 Business Wire
Mar-09-17 11:21AM  Billionaire Barry Rosensteins Top Q4 Moves: Alphabet (GOOG), Bristol-Myers (BMY), More at Insider Monkey
12:52AM  [$$] Bristol-Myers Squibb Names New R&D Chief at The Wall Street Journal
12:18AM  PRESS DIGEST - Wall Street Journal - March 9 Reuters
Mar-08-17 04:37PM  BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib
04:22PM  This Pharma Firm Is Beating The Pack In Getting Drugs To Market
12:24PM  Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer Business Wire
11:57AM  5 Stocks Insiders Are Loading Up On
11:37AM  [$$] Bristol-Myers Squibb Names New R&D Chief at The Wall Street Journal
11:08AM  Pharma says high prices fund drug development. This study says otherwise at MarketWatch
09:00AM  Bristol-Myers Squibb to Take Part in Barclays Global Health Care Conference Business Wire
08:04AM  Forget the Distractions: Bristol-Myers Squibb Is a Bargain at Motley Fool
12:32AM  Race Tightens for Next Wave of Cancer Drugs at The Wall Street Journal
Mar-07-17 11:03AM  The Big Reason Bristol-Myers Squibb Company Stock Exploded 15% Higher in February at Motley Fool
09:32AM  Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
09:21AM  Is Portola Pharmaceuticals Balance Sheet Safe? at Motley Fool
08:21AM  What Illumina's and Bristol-Myers Squibb's Latest GRAIL Moves Mean for Investors at Motley Fool
Mar-06-17 06:32PM  AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?
01:29PM  Bristol-Myers Squibb: Don't Get Your Hopes Up at
12:23PM  Race Tightens for Next Wave of Cancer Drugs at The Wall Street Journal
10:00AM  Japan Joins Trump in Drug Price War Crimping Pharma Profits
08:46AM  Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
08:30AM  Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session Business Wire
Mar-05-17 10:20AM  Insider Buying Steady as Market Again Hits All-Time Highs: Arconic, Murphys USA, Bristol-Myers, Avon and More
Mar-04-17 07:20PM  Weekly Top Insider Buys Highlight for the Week of March 3
Mar-03-17 09:32AM  Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4
08:33AM  Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug
Mar-02-17 04:34PM  Bristol-Myers Squibb Announces Dividend Business Wire
09:29AM  Director at Giant Drugmaker Buys New Stake Amid Takeover Speculations and Activist Pressure, Plus Other Insider Trading at Insider Monkey
Mar-01-17 06:20PM  Bristol-Myers Squibb to Present Data That Advances Understanding of Effects of Immuno-Oncology Therapies on Cancer Biology and Patient Outcomes at AACR 2017 Business Wire
05:42PM  Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
05:15PM  Drugs stocks shrug off Trump warning
02:46PM  Jana Partners' Largest 4th-Quarter Buys
02:37PM  Bristol-Myers Squibb Co. : BMY-US: Dividend Analysis : January 06th, 2017 (record date) : By the numbers : March 1, 2017
10:40AM  Exelixis, Inc. Turns a Profit, but Don't Get Too Excited at Motley Fool
10:04AM  [$$] Cancer Test Makers Raise Nearly $1 Billion at The Wall Street Journal
08:10AM  Bristol-Myers Squibb Expands Focus on Precision Medicine with Investment and Planned Collaboration with GRAIL on Blood-Based Cancer Screening Business Wire
08:06AM  Carl Icahn Takes Aim at Bristol-Myers Squibb at Motley Fool
07:37AM  AstraZenecas New Products May Offer 2017 Growth Opportunities
07:30AM  [$$] Gormley's Take: With Biotech Talent In Demand, CEO Takes Helm at Two Companies at The Wall Street Journal
06:54AM  Short Sellers Pile On Pfizer After Buyout Rumors
Feb-28-17 07:14PM  [$$] OrbiMed Logs Two Decades of Novel Attacks on Cancer at The Wall Street Journal
03:05PM  Why AstraZenecas Revenues Are Expected to Fall in 2017
01:10PM  What Analysts Are Recommending for AstraZeneca in 2017
11:46AM  Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
10:35AM  Eli Lilly & Co.s Valuation after Its 4Q16 Earnings Report
09:07AM  Bristol-Myers Squibb Is Focused on Creating Shareholder Value in 2017
07:39AM  Merck Expected to Witness Rise in Its Net Profit Margin in 2017
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. The company has collaboration with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,511015,250Aug 03 04:56 PM
ANDREOTTI LAMBERTODirectorJul 08Sale75.0411,600870,461368,499Jul 11 05:12 PM
ANDREOTTI LAMBERTODirectorJul 07Sale73.8611,600856,776380,099Jul 11 05:12 PM
Blin EmmanuelSVP, Chief Strategy OfficerJul 02Option Exercise0.00951012,516Jul 06 05:58 PM
Cuss Francis MEVP & CSOJul 01Option Exercise0.003,6550291,628Jul 06 05:58 PM
Gordon MurdoEVP, Chief Commercial OfficerJul 01Option Exercise0.002,335014,950Jul 06 05:58 PM
ANDREOTTI LAMBERTODirectorJun 29Sale72.799,800713,342392,194Jun 30 05:42 PM
ANDREOTTI LAMBERTODirectorJun 28Sale71.6713,400960,396390,394Jun 30 05:42 PM
Elicker John ESVP, Public Affairs & IRJun 14Sale72.6911,820859,21955,011Jun 16 04:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 20Sale70.7930,2012,137,838184,694May 24 05:04 PM
Caldarella Joseph CSVP & ControllerMay 16Sale72.473,519255,00455,238May 17 04:46 PM
Caforio GiovanniChief Executive OfficerMay 05Option Exercise0.008,0400134,549May 09 04:42 PM
Caforio GiovanniChief Executive OfficerMay 03Option Exercise24.7950,4551,250,602145,958May 05 04:31 PM
Caforio GiovanniChief Executive OfficerMay 03Sale71.3134,5942,466,885117,118May 05 04:31 PM
ANDREOTTI LAMBERTODirectorMay 02Option Exercise26.04234,7206,112,787671,514May 04 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyMay 02Sale71.9522,2181,598,65221,971May 04 05:28 PM
ANDREOTTI LAMBERTODirectorMay 02Sale71.88234,72016,870,792436,794May 04 05:28 PM
ANDREOTTI LAMBERTODirectorApr 05Sale66.0011,600765,626436,794Apr 06 04:18 PM
ANDREOTTI LAMBERTODirectorApr 04Sale65.7911,600763,216448,394Apr 06 04:18 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554025,260Apr 05 04:59 PM